Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

A new study investigated the impact of a monoclonal anti-thymic stromal lymphopoietin (TSLP) antibody on subcutaneous allergen immunotherapy (SCIT) efficacy among patients with allergic rhinitis.

3 Nov 2022

New control system could be used to finely tune the production of useful proteins

Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.

1 Nov 2022

Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus

New research discussed the structure and life cycle of respiratory syncytial virus (RSV), the current research on the treatment and prevention of RSV infections, and the advancements in RSV mRNA vaccine technology after the surge in vaccine research during the COVID-19 pandemic.

1 Nov 2022

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.

31 Oct 2022

New insights on antibody response against SARS-CoV-2 Omiron sublineages

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research question.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

Antibody-mediated protection against symptomatic COVID achieved at low serum neutralizing titers

In a recent study posted to the medRxiv* preprint server, researchers in the United States assessed the efficiency of protection mediated by antibodies against symptomatic coronavirus disease 2019 (COVID-19) at low serum-neutralizing titers.

24 Oct 2022

Exploring SARS-CoV-2-associated endothelial dysfunction

A new study described the evidence, mechanisms, and therapies for endothelial dysfunction in coronavirus disease 2019 (COVID-19).

21 Oct 2022

Immune-suppressing drug reverses symptoms of delirium in mice

Investigators from the departments of Neurology, Neurosurgery, Psychiatry, Medicine, and Biomedical Sciences at Cedars-Sinai have shown that an immune-suppressing drug similar to one used to treat severe COVID-19 reversed symptoms of delirium in mice whose lungs were injured during mechanical breathing assistance.

19 Oct 2022

Did the risk of severe COVID-19 in the immunodeficient population of the UK change following vaccination deployment?

Researchers evaluated the changing risk of severe COVID-19 outcomes in individuals with primary and secondary immunodeficiencies in the context of COVID-19 vaccinations.

17 Oct 2022

Omicron sublineage BA.2.75.2 largely resistant to several monoclonal antibody antiviral treatments

A study at Karolinska Institutet in Sweden shows that the coronavirus variant BA.2.75.2, an Omicron sublineage, largely evades neutralizing antibodies in the blood and is resistant to several monoclonal antibody antiviral treatments.

14 Oct 2022

Study determines how fibroblasts play a role in tumor's ability to generate anti-HER2 therapy resistance

A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumor's ability to generate resistance to the most common biological treatment for HER2.

14 Oct 2022

Will covid spike again this fall? 6 tips to help you stay safe

Last year, the emergence of the highly transmissible omicron variant of the covid-19 virus caught many people by surprise and led to a surge in cases that overwhelmed hospitals and drove up fatalities. Now we're learning that omicron is mutating to better evade the immune system.

14 Oct 2022

Cat allergen immunotherapy works better and more quickly when combined with monoclonal antibody

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found.

11 Oct 2022

The duration of the infectious stage of individuals infected with the SARS-CoV-2 Omicron variant

Researchers demonstrated clinical features and infectivity of the currently dominant SARS-CoV-2 variant of concern Omicron, compared to Delta, the previously dominant VOC.

3 Oct 2022

Universal vaccine advancement through AI and recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng and Dr. Lurong Pan about how AI computing can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

From Sino Biological Inc. 3 Oct 2022

Houston Methodist researchers receive CPRIT funding to research two of the most lethal cancers

Two Houston Methodist cancer researchers have been awarded a half million dollars in funding from the Cancer Prevention and Research Institute of Texas to further research two of the most lethal, difficult-to-treat cancers that all-too-often have poor prognoses.

28 Sep 2022

Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, primarily causes mild to moderate upper-respiratory tract illness. However, some individuals with COVID-19 develop severe infections and require hospital admission.

27 Sep 2022

Monoclonal Antibody News and Research

Further Reading

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

New control system could be used to finely tune the production of useful proteins

Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

New insights on antibody response against SARS-CoV-2 Omiron sublineages

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

Antibody-mediated protection against symptomatic COVID achieved at low serum neutralizing titers

Exploring SARS-CoV-2-associated endothelial dysfunction

Immune-suppressing drug reverses symptoms of delirium in mice

Did the risk of severe COVID-19 in the immunodeficient population of the UK change following vaccination deployment?

Omicron sublineage BA.2.75.2 largely resistant to several monoclonal antibody antiviral treatments

Study determines how fibroblasts play a role in tumor's ability to generate anti-HER2 therapy resistance

Will covid spike again this fall? 6 tips to help you stay safe

Cat allergen immunotherapy works better and more quickly when combined with monoclonal antibody

The duration of the infectious stage of individuals infected with the SARS-CoV-2 Omicron variant

Universal vaccine advancement through AI and recombinant technology

Houston Methodist researchers receive CPRIT funding to research two of the most lethal cancers

Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News